{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:30:37Z","timestamp":1794353437831,"version":"4.9.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010756","name":"Health and Social Care Research and Development Division","doi-asserted-by":"publisher","award":["EAT\/5815\/25"],"award-info":[{"award-number":["EAT\/5815\/25"]}],"id":[{"id":"10.13039\/501100010756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT 13600061"],"award-info":[{"award-number":["WT 13600061"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR200927"],"award-info":[{"award-number":["NIHR200927"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijid.2026.109038","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:31:44Z","timestamp":1786033904000},"page":"109038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Effectiveness of nirsevimab and maternal RSVpreF vaccination against infant hospitalization across the island of Ireland"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-7012","authenticated-orcid":false,"given":"Bryony","family":"Treston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4883-4202","authenticated-orcid":false,"given":"Shaun","family":"O\u2019Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-8347","authenticated-orcid":false,"given":"Michael","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Marlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3866-1344","authenticated-orcid":false,"given":"Thomas","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8634-7210","authenticated-orcid":false,"given":"Mark","family":"Lyttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Roland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9452-7716","authenticated-orcid":false,"given":"Thomas","family":"Waterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Geoghegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9244-9961","authenticated-orcid":false,"given":"Helen","family":"Groves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10340","key":"10.1016\/j.ijid.2026.109038_bib0001","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ijid.2026.109038_bib0002","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/irv.12726","article-title":"Human respiratory syncytial virus and influenza seasonality patterns\u2014early findings from the WHO global respiratory syncytial virus surveillance","volume":"14","author":"Chadha","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"issue":"6","key":"10.1016\/j.ijid.2026.109038_bib0003","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S2352-4642(25)00102-6","article-title":"180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial","volume":"9","author":"Munro","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.ijid.2026.109038_bib0004","first-page":"1451","volume":"388","author":"Kampmann","year":"2023"},{"key":"10.1016\/j.ijid.2026.109038_bib0005","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2025-075223","article-title":"Maternal RSV vaccination, infant Nirsevimab, or both: interim analysis of a randomized trial","author":"Rostad","year":"2026","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.ijid.2026.109038_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(24)00811-9","article-title":"Full season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study","volume":"25","author":"Mallah","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.ijid.2026.109038_bib0007","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJMoa2314885","article-title":"Nirsevimab and hospitalization for RSV bronchiolitis","volume":"391","author":"Assad","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ijid.2026.109038_bib0008","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2352-4642(25)00155-5","article-title":"Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study","volume":"9","author":"Williams","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"issue":"9","key":"10.1016\/j.ijid.2026.109038_bib0009","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1473-3099(25)00156-2","volume":"25","author":"P\u00e9rez Marc","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.109038_bib0010","unstructured":"UK Health Security Agency (UKHSA). RSV maternal vaccination coverage in England: 2025. https:\/\/www.gov.uk\/government\/publications\/rsv-immunisation-for-older-adults-and-pregnant-women-vaccine-coverage-in-england\/rsv-maternal-vaccination-coverage-in-england-march-2025 [Accessed 13 May 2026]."},{"key":"10.1016\/j.ijid.2026.109038_bib0011","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2352-4642(26)00075-1","article-title":"Effectiveness of nirsevimab immunisation after birth versus RSVpreF maternal vaccination in preventing RSV-related hospitalisations in infants: a population-based retrospective cohort study","volume":"11","author":"Valtuille","year":"2026","journal-title":"Lancet Child Adolesc Health"},{"issue":"9","key":"10.1016\/j.ijid.2026.109038_bib0012","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jama.2025.24082","article-title":"Nirsevimab vs RSVpreF vaccine for respiratory syncytial virus\u2013related hospitalization in newborns","volume":"335","author":"Jabagi","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2026.109038_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1686581","article-title":"Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria","volume":"13","author":"H\u00f6ck","year":"2025","journal-title":"Front Public Health"},{"issue":"4","key":"10.1016\/j.ijid.2026.109038_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.5695","article-title":"RSV prevention products and severe RSV-associated disease among infants","volume":"9","author":"Bennett","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ijid.2026.109038_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3201\/eid3201.250870","article-title":"Reduced emergency department visits and hospitalizations in infants after Universal Respiratory Syncytial Virus Immunization, Italy, 2024\u201325","volume":"32","author":"Villa","year":"2026","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijid.2026.109038_bib0016","first-page":"63","article-title":"Real-world impact of nirsevimab immunisation and maternal RSV vaccination against respiratory disease on emergency department attendances and admissions: a multinational retrospective analysis","volume":"63","author":"Perramon-Malavez","year":"2026","journal-title":"Lancet Reg Health \u2013 Eur"},{"issue":"7","key":"10.1016\/j.ijid.2026.109038_bib0017","first-page":"367","article-title":"Impact of nirsevimab immunization on RSV infections attended in the pediatric emergency department: first results in a tertiary hospital in Madrid","volume":"42","author":"M\u00c1","year":"2024","journal-title":"Enferm infecc microbiol clin"},{"issue":"5","key":"10.1016\/j.ijid.2026.109038_bib0018","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s40121-026-01333-4","article-title":"Impact of Nirsevimab on pediatric RSV-related lower Respiratory tract infections: a retrospective pre\u2013Post observational study in Tuscany","volume":"15","author":"Nieddu","year":"2026","journal-title":"Italy Infect Dis Ther"},{"key":"10.1016\/j.ijid.2026.109038_bib0019","unstructured":"Department of Health Ireland. Minister for Health announces Government approval for a new Respiratory Syncytial Virus (RSV) Immunisation Pathfinder Programme. Dublin, Ireland 2024 https:\/\/www.gov.ie\/en\/press-release\/b0e06-minister-for-health-announcesgovernment-approval-for-a-new-respiratory-syncytial-virus-rsv-immunisation-pathfinder-programme\/ [Accessed 1 May 2026]."},{"key":"10.1016\/j.ijid.2026.109038_bib0020","unstructured":"UK Health Security Agency (UKHSA). Respir syncytial virus: green book, chapter 27a. 2025 https:\/\/www.gov.uk\/government\/publications\/respiratory-syncytial-virus-the-greenbook-chapter-27a [Accessed 1 May 2026]."},{"issue":"4","key":"10.1016\/j.ijid.2026.109038_bib0021","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijid.2026.109038_bib0022","unstructured":"Health Do. Minister for health announces government approval for a new respiratory syncytial virus (RSV) immunisation pathfinder programme. Dublin, Ireland 2024 https:\/\/www.gov.ie\/en\/press-release\/b0e06-minister-for-health-announcesgovernment-approval-for-a-new-respiratory-syncytial-virus-rsv-immunisation-pathfinder-programme\/ [Accessed 1 May 2026]."},{"key":"10.1016\/j.ijid.2026.109038_bib0023","unstructured":"Agency UHS. Respir syncytial virus: green book, chapter 27a. 2025 https:\/\/www.gov.uk\/government\/publications\/respiratory-syncytial-virus-the-greenbook-chapter-27a [Accessed 1 May 2026]."},{"key":"10.1016\/j.ijid.2026.109038_bib0024","doi-asserted-by":"crossref","DOI":"10.12688\/wellcomeopenres.16778.3","article-title":"Update to: study pre-protocol for \u201cBronchStart - the impact of the COVID-19 pandemic on the timing, age and severity of respiratory syncytial virus (RSV) emergency presentations; a multi-centre prospective observational cohort study\u201d","volume":"6","author":"Williams","year":"2024","journal-title":"Wellcome Open Res"},{"issue":"2","key":"10.1016\/j.ijid.2026.109038_bib0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2024.5633","article-title":"Test-negative study designs for evaluating vaccine effectiveness","volume":"332","author":"Dean","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2026.109038_bib0026","article-title":"The effect of the COVID-19 pandemic on influenza-related hospitalization, intensive care admission and mortality in children in Canada: a population-based study","volume":"7","author":"Groves","year":"2022","journal-title":"Lancet Reg Health - Am"},{"issue":"1","key":"10.1016\/j.ijid.2026.109038_bib0027","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1186\/s12879-024-09509-4","article-title":"Global patterns of rebound to normal RSV dynamics following COVID-19 suppression","volume":"24","author":"Thindwa","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2026.109038_bib0028","article-title":"Monitoring effectiveness of nirsevimab immunization against RSV hospitalization using surveillance data: a test-negative case-control study, Spain, October 2024-March 2025","volume":"154","author":"Campos Mena","year":"2025","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.ijid.2026.109038_bib0029","article-title":"Effectiveness of nirsevimab against hospitalisation for RSV-bronchiolitis during high RSV-B circulation in the second year of nationwide implementation in France: a test-negative case-control study","volume":"58","author":"Furgier","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ijid.2026.109038_bib0030","article-title":"Nirsevimab effectiveness, number needed to immunize and impact on severe RSV outcomes, a test-negative study in Quebec, Canada","volume":"57","author":"Carazo","year":"2026","journal-title":"Lancet Reg Health - Am"},{"issue":"3","key":"10.1016\/j.ijid.2026.109038_bib0031","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamapediatrics.2025.5778","article-title":"Effectiveness and impact of maternal RSV immunization and nirsevimab on medically attended RSV in US children","volume":"180","author":"Moline","year":"2026","journal-title":"JAMA Pediatr"},{"issue":"4","key":"10.1016\/j.ijid.2026.109038_bib0032","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1473-3099(25)00624-3","article-title":"Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case-control study and cohort analysis","volume":"26","author":"McLachlan","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.109038_bib0033","unstructured":"Northern Ireland Public Health Agency. RSV vaccination for infant protection (pregnant women) in Northern Ireland: end of programme year report. 2025 https:\/\/www.publichealth.hscni.net\/services-and-teams\/public-health-services\/health-protection\/vaccination-and-immunisation-5 [accessed 4 May 2026]."},{"key":"10.1016\/j.ijid.2026.109038_bib0034","unstructured":"Prevention CuCfDCa. RSV Immun Guid Infants Young Child 2025. https:\/\/www.cdc.gov\/rsv\/hcp\/vaccine-clinical-guidance\/infants-young-children.html [Accessed 13 May 2026]."},{"issue":"5","key":"10.1016\/j.ijid.2026.109038_bib0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/PEC.0000000000003339","article-title":"Changes in care in Spanish pediatric emergency departments after the first immunization with Nirsevimab","volume":"41","author":"Vazquez-Lopez","year":"2025","journal-title":"Pediatr Emerg Care"},{"key":"10.1016\/j.ijid.2026.109038_bib0036","unstructured":"Scotland PH. PHS vaccin surveill 2026. https:\/\/scotland.shinyapps.io\/phs-vaccination-surveillance\/ [Accessed 13 May 2026]."},{"key":"10.1016\/j.ijid.2026.109038_bib0037","unstructured":"Ireland PHAN. RSV vaccination for infant protection (Pregnant women) in Northern Ireland end of programme year report 2024\/25 2026 https:\/\/www.publichealth.hscni.net\/services-and-teams\/public-health-services\/health-protection\/vaccination-and-immunisation-5 [Accessed 13 May 2026]."},{"key":"10.1016\/j.ijid.2026.109038_bib0038","unstructured":"Hanrahan M PA, O\u2019Moore \u00c9. Respiratory Syncytial Virus (RSV) Immunisation Pathfinder Programme 2024\u20132025: evaluation \u2013 executive summary. Dublin: HSE Natl Health Prot Off 2025 https:\/\/www.hpsc.ie\/a-z\/respiratory\/respiratorysyncytialvirus\/immunisation\/evaluation\/Executive%20Summary%20RSV%20Immunisation%20Pathfinder%20Programme_1.0.pdf [Accessed 13 May 2026]."},{"key":"10.1016\/j.ijid.2026.109038_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2026.128344","article-title":"Protecting infants from respiratory syncytial virus (RSV) in Ireland: impact of a national nirsevimab immunisation programme, 2024\/2025","volume":"76","author":"Paris","year":"2026","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2026.109038_bib0040","unstructured":"O\u2019Hagan S, Cunningham S, Drysdale SB, Groves H, Hunt S, Iskander D, et al. PERUKI & BronchStart Collaboration. Maternal recall of receipt of RSVpreF during pregnancy [ePoster]. 9th ReSViNET RSVVW\u201926 Conference; 2026 Feb 17\u201320; Rome, Italy. 2026."},{"key":"10.1016\/j.ijid.2026.109038_bib0041","unstructured":"Executive HS. New appointments opened for RSV immunisation clinics. 2025. https:\/\/about.hse.ie\/news\/new-appointments-opened-for-rsv-immunisation-clinics\/ [Accessed 13 May 2026]."}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226006739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226006739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:52:38Z","timestamp":1791816758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226006739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"alternative-id":["S1201971226006739"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.109038","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of nirsevimab and maternal RSVpreF vaccination against infant hospitalization across the island of Ireland","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.109038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"109038"}}